Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant systemic therapy.
Carbone PP, Nixon DW, Fennelly J, Greenberg E, Henderson IC, Hortobagyi G, Kennedy BJ, Trainin N, Scanlon EF. Carbone PP, et al. Cancer. 1990 May 1;65(9 Suppl):2108-9. doi: 10.1002/1097-0142(19900501)65:9+<2108::aid-cncr2820651404>3.0.co;2-f. Cancer. 1990. PMID: 2328476 No abstract available.
Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial.
Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Hortobagyi GN, Pusztai L, Kalinsky K. Abdou Y, et al. Among authors: hortobagyi gn. J Natl Cancer Inst. 2024 Dec 5:djae314. doi: 10.1093/jnci/djae314. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39656951
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D. Hortobagyi GN, et al. Ann Oncol. 2024 Oct 21:S0923-7534(24)04064-X. doi: 10.1016/j.annonc.2024.10.015. Online ahead of print. Ann Oncol. 2024. PMID: 39442617 Free article.
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.
Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Yam C, et al. Among authors: hortobagyi gn. Cancer Res Commun. 2024 Oct 1;4(10):2823-2834. doi: 10.1158/2767-9764.CRC-24-0255. Cancer Res Commun. 2024. PMID: 39356138 Free PMC article. Clinical Trial.
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.
Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopoulou E, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. Chavez-MacGregor M, et al. Among authors: hortobagyi gn. J Clin Oncol. 2024 Sep 1;42(25):3012-3021. doi: 10.1200/JCO.23.02344. Epub 2024 Jun 4. J Clin Oncol. 2024. PMID: 38833643 Clinical Trial.
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
Chen CS, Zirpoli G, Budd GT, Barlow WE, Pusztai L, Hortobagyi GN, Albain KS, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL. Chen CS, et al. Among authors: hortobagyi gn. Cancer Chemother Pharmacol. 2024 Aug;94(2):311-321. doi: 10.1007/s00280-024-04680-6. Epub 2024 May 30. Cancer Chemother Pharmacol. 2024. PMID: 38814343 Clinical Trial.
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Gallagher EJ, Moore H, Lacouture ME, Dent SF, Farooki A, Goncalves MD, Isaacs C, Johnston A, Juric D, Quandt Z, Spring L, Berman B, Decker M, Hortobagyi GN, Kaffenberger BH, Kwong BY, Pluard T, Rao R, Schwartzberg L, Broder MS. Gallagher EJ, et al. Among authors: hortobagyi gn. NPJ Breast Cancer. 2024 Jan 31;10(1):12. doi: 10.1038/s41523-024-00613-x. NPJ Breast Cancer. 2024. PMID: 38297009 Free PMC article.
1,108 results